Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib vs Gefitinib in Advanced NSCLC
NCT00059722Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of vandetanib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Sanofi. Primary endpoints: Time to progression and Incidence, CTC grade and type of AEs, laboratory abnormalities, vital signs, ECG changes. Started May 2003; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00059722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059722.